Select a Region North America


Faruk Abdullah

President, Professional Services and Chief Business Officer


Consulting (Strategy Management & Regulatory)

Faruk is a life sciences professional with extensive experience addressing a broad range of strategic issues, including corporate development, portfolio planning, and launch excellence. Prior to joining EVERSANA MANAGEMENT CONSULTING he helped clients apply advanced analytic software technologies to draw unique insights from clinical and commercial data and focused on shaping and executing strategic initiatives for large- and mid-cap life sciences companies.

In addition to being a strategic advisor, Faruk has contributed to entrepreneurial efforts, developing products in both the therapeutic and medical device spaces. He has authored a number of articles that have helped companies consider novel approaches to developing and commercializing their products. He has shared unique perspectives on how companies can adapt their commercial models to an evolving healthcare ecosystem and offered insights on how organizations can rethink the development and integration of analytic capabilities to inform strategic decisions.

Faruk holds an MBA from Harvard Business School and a BS in electrical engineering from Northwestern University.

Articles by Faruk Abdullah

Maximize In-Licensing Growth

In-licensing is a significant growth lever for a variety of reasons, including: Serving as a risk mitigation tool Reinforce a company’s therapeutic area footprint Serving as a growth catalyst channel to further diversify your pipeline and product portfolio. A Once-in-a-Lifetime Moment of Market Conditions The opportunity at hand for large pharma has been created by the once-in-a-lifetime, current market dynamics. These macroeconomic factors include: A decade-long trend of funding being funneled into small and mid-sized pharma = the number of companies with small assets coming to market has increased Public markets have contracted over the last 18 months and companies are now hitting an evaluation shortfall. These two conditions have […]

Three Keys to Value for Unlocking the Promise of Cell Therapies

The cell therapy market continues to grow. Estimated at $101 billion in 2021, the global cell therapy market is projected to reach $247 billion by 2028, a CAGR of 13.64%.1  The revenue generation is being driven by technological advancements in manufacturing processes and developments in CAR T-cell therapy for solid tumors, and the approvals and clinical success of Novartis’ Kymriah and Gilead Sciences’ Yescarta are giving encouragement to other developers of cellular immunotherapies.2  In the U.S. this year, the cell and gene industry is anticipated to see its highest annual number of regulatory approvals.3 Recent approvals include Bristol Myers Squibb’s Breyanzi cancer cell therapy, which the FDA cleared for an […]

Overcome In-Licensing Barriers to Increase Throughput of Assets

In-licensing is an important growth channel for pharmaceutical companies as they continue to seek more catalysts for growth. In-licensing is used to expand or consolidate a company’s position in a therapy area but can oftentimes be limited by internal restraints. Common Barriers to In-Licensing: Capacity and Capability Constraints Many times, companies are limited in in-licensing more clinically and commercially viable assets due to commercial capacity and capability constraints. In fact, observations from recent due diligence efforts indicate companies eliminate at least 20-30% of potentially viable assets due to not having enough resources to commercialize the asset or not having the unique capabilities necessary to commercialize based on asset or market […]

Reigniting Revenue for Established Brands

Established brands do not require significant proactive investment or attention from commercial teams and generate revenue for biopharma companies to reinvest and improve healthcare value for patients, providers and payers. Established brands have seen a decrease in utilization and patient access due to the pandemic, making them vulnerable to negative financial impacts that are difficult to rebound from. For example, we analyzed a sample of these brands to understand the financial impact they experienced during the COVID-19 pandemic. The results indicated a massive revenue reduction that cost these brands over $3.9B of revenue over a nine-month time frame. Manufacturers have several options available to change the trajectory and maximize the […]

Reignite Established Brands — Actual Use Case

EVERSANA™ REIGNITE Commercialization serves as a catalyst for biopharma companies to address the management of their established brand portfolios. In a recent study, EVERSANA reviewed a comprehensive number of established brands and implemented the EVERSANA REIGNITE Commercialization model to slow financial loss and make a positive impact on revenue. With a combined investment, these established brands experienced a 1:3 to 3:6 return on investment ratios. This critical ROI observation illustrates how established brands have the opportunity to change the trajectory of these product portfolios and maximize value, utilizing resources already dedicated to the brand. Read the complete white paper on Reigniting Value in Established Brands.

Podcast: Achieving Cell and Gene Therapy Commercial Excellence

There is no question about the incredible clinical impact cell and gene therapies (CGTs) can have on the lives of patients. However, this impact is the result of innovation that does not equate to a simple, straightforward commercialization process. The commercialization and management requirements of these treatments are just as complex as their innovative science. Commercialization of cell and gene therapies is significantly more challenging compared to traditional biopharma products.​ Faruk Abdullah, Head of U.S. Consulting, EVERSANA™ MANAGEMENT CONSULTING and Maria Kirsch, General Manager, Patient Services share insight on building the future commercialization model designed specifically for CGTs, including: Key differences between CGTs and traditional therapies Ideas, tactics and techniques […]

Driving Commercial Excellence for CAR-T

In this session from the 6th Annual CAR-TCR Summit, Faruk Abdullah, Head of U.S. Consulting, EVERSANA™ MANAGEMENT CONSULTING and Maria Kirsch, SVP & Head of Patient Services share insight on building the future commercialization model designed specifically for CAR-T, including: Key differences between CAR-T and traditional therapies Ideas, tactics and techniques needed to address CAR-T’s unique challenges Navigating the healthcare ecosystem beyond oncology that requires a deep level of interaction and coordination with supply chain, hospital operations, nurses and other key stakeholders The need to not only showcase the product value proposition, but also train on the therapy’s MOA, administration and usage

Learning How to Play Dilution Dodgeball

The healthcare industry is reaching new heights in innovation, and as new drugs are founded, owners of biotech companies must decide whether or not they want to independently bring their product to market.  Developing and successfully commercializing a biopharma product is no small undertaking. The multi-year journey is fraught with clinical, financial and operational uncertainties that many companies fail to overcome. By time the company reaches commercialization, founders usually see more than 90% reduction in equity overall.  What if there was a low-risk alternative to circumvent equity dilution, allowing founders to have the best of both worlds? In today’s market – this option does exist.  Download this article to learn how to play “Dilution Dodgeball” as you successfully commercialize your product and […]

Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth

As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market put on a company that chooses to launch and commercialize its product independently? The universe of nanocap and microcap pharma companies continues to grow, creating a backlog of companies trying to chart the course toward becoming a mid-cap or even large-cap company. Clearly, the primary means of reaching that goal is successfully launching and commercializing […]

The Crush: How Covid-19 Is Impacting Mature Brand Revenue & Long-Term Value

The impact of COVID is reverberating across all aspects of society and business. In the healthcare industry, hundreds of thousands of patients are not getting proper access to and utilization of therapies that can improve their clinical outcomes. The clinical consequences of this will lead to compromised patient outcomes and further healthcare cost increases. This also leads to negative strategic and financial ramifications for biopharma manufacturers who produce these therapies. Billions of dollars of revenue and tens of billions of dollars of market valuation have been erased over the last year due to COVID-related market conditions, for every dollar of revenue lost can lead to a disproportionate loss in market […]

Moving Forward in Pharma: Reigniting Revenue for Mature Brands

The world will be moving forward with immeasurable effects from the COVID-19 pandemic, as will the pharmaceutical industry. Fully understanding the impact that the pandemic will have on pharma will take years; however, there are future indications emerging for mature brands. Mature brands, or non-promoted in-line brands, are the bread-and-butter products for pharma companies in a normal market. These brands have historically provided reliable revenue support, allowing manufacturers to research and develop drugs in new treatment areas. Now, approximately $31.4B of these “recurring” revenue stream brands are facing failure due to COVID-19-related impacts. As COVID-19 cuts into pharma’s bottom line, manufacturers need to begin strategizing how they can address the […]

The Chronic Microcap Trap: How Launch Is The Escape for True Growth

Pre-commercial pharma companies face a common choice: commercialize products independently or collaborate with another pharmaceutical company as a commercialization partner. As the C-suite leaders in these organizations wrestle with the pros and cons of this choice, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market put on a company that chooses to launch and commercialize its product independently? This white paper dives deep into the data and discusses how the average market capitalization of a cohort of public companies that developed paths to launch their own products (including […]

Interested in scheduling a meeting or speaking event?